
Clinical Trials - May 30, 2016
Novo’s Semaglutide shows positive results
Novo Nordisk’s Semaglutide demonstrates superior glycaemic control vs insulin glargine U100 in adults with type 2 diabetes shows a new study. Findings from a phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment with semaglutide, administered once-weekly, significantly improved glycaemic control compared to insulin glargine U100 in adults with […]